Munich Startup
Modiblast Pharma

Modiblast Pharma

Modiblast Pharma is working to enter the clinical development phase with novel dendritic cell therapies for hematologic malignancies. The focus is on the core challenge of acute myeloid leukemia (AML) and myelodysplastic syndromes...

Founded2020
Business ModelB2B
IndustryLife Science
This content was machine translated.

About Modiblast Pharma

Modiblast Pharma is working to enter the clinical development phase with novel dendritic cell therapies for hematologic malignancies. The focus is on the core challenge of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS): the extremely high relapse rate after successful initial therapy. The Modiblast approach (3 patents granted) combines immunomodulators to stimulate blasts (cancer cells) to differentiate into leukemia-specific dendritic cells (DCleu) in the patient (in vivo). This causes both innate and adaptive immune cells in blood and tissue to kill remaining or recurring blasts and generate memory cells. Unlike, for example, CAR-T, it is not necessary to identify and select specific target molecules. Furthermore, no complicated and expensive ex vivo cell extraction and preparation procedures or GMP facilities are required. Our long-term goal is to provide an easy-to-use, self-administered medicine that can stabilize remissions or halt disease progression. This therapy can also normalize platelet and neutrophil counts. The next step in clinical development is a phase 1a/2b study that recently passed scientific consultation with the BfArM.

More like this

Discover more articles, startups, and events from the ecosystem

Five New Launches: Isar Aerospace Fills Its 2028 Flight Schedule
Deals

Five New Launches: Isar Aerospace Fills Its 2028 Flight Schedule

22.09.26
3 Min.
Multi-Million Deal for Munich AI Startup Grubel
Deals

Multi-Million Deal for Munich AI Startup Grubel

22.09.26
4 Min.
Code Gaia Takes Over Global Climate Clients
Deals

Code Gaia Takes Over Global Climate Clients

22.09.26
3 Min.